Trial register facet
Trial records in prediabetes and progression to type 2 diabetes
10 records bearing on prediabetes and progression to type 2 diabetes.
Showing 0 records on this page
Records
10 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STEP-5 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 304 | 2022 | High |
| STEP-5-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-5-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-5-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-5-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| SCALE-PREDIABETES | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,254 | 2017 | Moderate |
| SCALE-PREDIABETES-OLEprogramme record | Liraglutide | Phase 3 | Reported | Single-arm open-label | — | 2017 | Very low |
| SCALE-PREDIABETES-ELDERLYprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SCALE-PREDIABETES-BIOMARKERprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SCALE-PREDIABETES-DDIprogramme record | Liraglutide | Phase 1 | Reported | Randomised crossover | — | 2017 | Very low |